1. Selective modulation of CD4+ T cells from lupus patients by a promiscuous, protective peptide analog.
- Author
-
Monneaux F, Hoebeke J, Sordet C, Nonn C, Briand JP, Maillère B, Sibillia J, and Muller S
- Subjects
- Amino Acid Sequence, CD4-Positive T-Lymphocytes immunology, HLA-DR Antigens metabolism, Humans, Interleukin-10 biosynthesis, Lymphocyte Activation, Molecular Sequence Data, Phosphorylation, CD4-Positive T-Lymphocytes drug effects, Lupus Erythematosus, Systemic immunology, Peptide Fragments pharmacology, Ribonucleoprotein, U1 Small Nuclear pharmacology
- Abstract
A peptide encompassing residues 131-151 of the spliceosomal U1-70K protein and its analog phosphorylated at Ser140 were synthesized as potential candidates for the treatment of patients with lupus. Studies in the MRL/lpr and (NZB x NZW)F1 lupus models have demonstrated that these sequences contain a CD4+ T cell epitope but administration of the phosphorylated peptide only ameliorates the clinical manifestations of treated MRL/lpr mice. Binding assays with soluble HLA class II molecules and molecular modeling experiments indicate that both peptides behave as promiscuous epitopes and bind to a large panel of human DR molecules. In contrast to normal T cells and T cells from non-lupus autoimmune patients, we found that PBMCs from 40% of lupus patients selected randomly and CFSE-labeled CD4+ T cells proliferate in response to peptide 131-151. Remarkably, however, we observed that phosphorylation of Ser140 prevents CD4+ T cells proliferation but not secretion of regulatory cytokines, suggesting a striking immunomodulatory effect of phosphorylated analog on lupus CD4+ T cells that was unique to patients. The analog might act as an activator of regulatory T cells or as a partial agonist of TCR.
- Published
- 2005
- Full Text
- View/download PDF